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HighincidenceofHCCismostlyduetothecombinationoftwomajorriskfactors,chronicinfectionwithhepatitisB(HBV)and/or
C (HCV) viruses and exposure to the mycotoxin aﬂatoxin B1, which induces a particular mutation at codon 249 in TP53 (R249S).
EightgenotypesofHBVarediverselyfoundinhighandlowincidenceareas.Regardlessofdocumentedstrongassociationsbetween
TP53 R249S mutation and HBV genotypes B, C, A or E, there is no report of such association for genotype D despite of the
presence of aﬂatoxin in areas with high prevalence of HBV genotype D. In Iran, 3% of the population is chronically infected with
HBV, predominantly genotype D. Twenty-one histologically conﬁrmed HCC cases from Iran were analyzed for TP53 R249S and
HBV double mutations 1762T/1764A, hallmarks of more pathogenic forms of HBV. We did not detect any of these mutations. In
addition, we report the only case identiﬁed so far carrying both R249S mutation and chronic HBV genotype D, a patient from The
Gambia in West Africa. This paper suggests that association between HBV genotype D and aﬂatoxin-induced TP53 mutation is
uncommon, explaining the relatively lower incidence of HCC in areas where genotype D is highly prevalent.
1.Introduction
Hepatocellular carcinoma (HCC) is the sixth most common
cancer, accounting for about 5% of all human cancers and
the second cause of cancer death in the world [1]. In 2008,
an estimated of 748,000 new cases of liver cancer occurred
and 696,000 people died of this cancer. Although liver cancer
is a global health problem and a major cause of mortality
and morbidity, low-income, tropical countries are more
commonly aﬀected, and 80% of cases occur in these regions,
especially in South-East Asia and Sub-Sahara Africa [2].
HCC is the third most common cancer in China with the
age-standardized rate (ASR) of 37.4 and 34.1 per 100,000
person-years in males and females, respectively. In Western
Africa, the ASR of HCC is 16.6 in males and 16.5 per 100,000
person-years in females, where this cancer accounts for the
second most common cancer [1]. Cancer risk is 2–7 times
higher in men than in women but this ratio varies across the
world.
The most important risk factors for liver carcinogenesis
include chronic infections with hepatitis B (HBV) and C
(HCV)viruses,chronicalcoholconsumption,andconsump-
tion of aﬂatoxin B1 (AFB1) contaminated food. With the
presence of about 2 billion people with past or present HBV
infectionacrosstheworldandmorethan350millionchronic
carriers, HBV remains one of the most common human
pathogens and a signiﬁcant public health problem. Diﬀerent
mechanisms are suspected to be responsible for its role in
liver carcinogenesis. HBV, a member of hepadnaviruses, has
a partially double-stranded DNA genome containing four
overlapping open reading frames: Pre-C/C, encoding the2 Hepatitis Research and Treatment
HBeAgandHBcAg;P,encodingtheviralpolymerase;Pre-S/S
encoding the three viral surface proteins; and X, producing
HBx protein. HBx is a 17.5KDa, 154 amino acid multi-
functional regulator protein that has been closely associated
with HCC. It is known that HBx stimulates HBV replication
and interferes with many cellular signaling pathways but its
precise role in human liver carcinogenesis is still unclear.
Furthermore, the integration of HBV in 80–90% of host
genome of HBV-infected HCC cases has been reported,
suggesting a mechanism of insertional mutagenesis. Several
studies have shown that C-terminal truncation of integrated
HBX may promote tumorigenesis [3–6].
HBV has a variable genome sequence and is currently
classiﬁed in eight diﬀerent genotypes (from A to H), the
prevalence of which varies geographically. Genotypes B and
C are the most prevalent HBV forms in high incidence areas
in South-East Asia, while genotype E is common in West
Africa and genotype D is the major genotype in eastern
Africa, Middle East, Central Asia, and India [7]. The diverse
oncogenicity of HBV genotypes has been studied by multiple
researchers [6, 8, 9]. However, the impact of their role in
molecular mechanisms of carcinogenesis has not been fully
investigated yet.
Epidemiological studies in high incidence areas indicate
that dietary AFB1 contributes to the development of HCC
and that the two main risk factors, HBV and AFB1,h a v ea
synergistic eﬀect in liver carcinogenesis [10]. Aﬂatoxins are a
group of mycotoxins that contaminate many sources of food
in hot and humid countries such as West Africa, parts of
China, South-East Asia, and regions of Latin America. The
molecular hallmark of AFB1 intoxication in relation to HCC
is a speciﬁc mutation at codon 249 of the TP53 gene. This
mutation is a single-base substitution at the third base of
codon 249 (AGG to AGT), which replaces an arginine “R”
by a serine “S”. This mutation has been reported in about
75% of HCC cases in high incidence areas (China or East
Africa). Such a mutation is not detected in HCC cases from
nonaﬂatoxin contaminated areas [11].
In addition, a double mutation in HBV genome cor-
responding to an adenine to thymine transversion at
nucleotide 1762, and a guanine to adenine transition at
nucleotide1764(1762T/1764A)hasbeenreportedasstrongly
associatedwithriskofHCCinhighincidenceareasofChina,
Thailand, or West Africa [12–15].
In this paper, we have analyzed HCC cases from Iran, a
Middle East/Central Asian country of moderate incidence of
HCC (ASR of 2.1 per 100,000 person-years in both sexes)
despite the relatively high prevalence of chronic carriage
of HBV, mainly genotype D [16–18], in the population
and the document presence of aﬂatoxin, at least levels, in
several components of the diet [19–21]. With the objective
of documenting possible association between genotype D
and molecular hallmarks of HCC detected in high incidence
areas, we have analyzed TP53 R249S mutations and HBV
double mutations. In addition, we are documenting one
case of a patient from West Africa with HBV genotype
Da n dTP53 R249S mutation. This study establishes that
association between TP53 R249S and HBV genotype D is
uncommon, providing a clue to explain the relatively modest
incidence of HCC in regions where this genotype is the most
common.
2.MaterialsandMethods
2.1. Case Selection. Thirty-four formalin ﬁxed paraﬃn
embedded (FFPE) HCC cases were selected from the pathol-
ogy archives of two hospitals (Shariati and Atieh) and one
day clinic (Tehran Gastroenterology and Hepatology Center)
in Tehran, based on the diagnosis, size of the tissue, and the
availability of the clinical data. All cases were histologically
and immunohistochemically conﬁrmed as primary HCC.
Cases were rereviewed by a pathologist at the International
Agency for Research on Cancer (BA-A) to conﬁrm the
diagnosis and to annotate tumor areas containing at least
70% of tumor cells. The study was conducted in accordance
with international ethical standards applicable both in Iran
andatIARC.Inparticular,caseswereretrospectivelyselected
from the pathology archives and were anonymized prior to
analysis. The HCC case from The Gambia was identiﬁed in
the context of a case-control study, the Gambia Liver Cancer
Study (GLCS), the design and ethical approval of which has
been previously described [22].
2.2.DNAExtraction. Sequentialsectionswerepreparedfrom
selected FFPE blocks, and DNA was extracted by using
QIAamp DNA MicroKit from QIAGEN (Hilden, Germany)
as described by the manufacturer. The quantity of extracted
DNA was measured by Nanodrop.
2.3. Detection of TP53 Mutations. For TP53 mutations
analysis,exon7(encompassingR249S)wasampliﬁedbyPCR
and directly sequenced. Sequencing was performed on an
Applied Biosystems PRISM 3100 Genetic Analyzer (Applied
Biosystems, Foster City, CA). Each PCR product was gener-
ated in duplicate, with one product sequenced in the forward
direction and the other in the reverse direction. In the
case of discordant sequencing results, the complementary
sequences were analyzed and the ﬁnal result was conﬁrmed
by sequencing a third, independent PCR product. Primers,
PCR, and sequencing conditions are described in detail on
the TP53 IARC database website at http://www-p53.iarc.fr/.
Chromatograms were analyzed semiautomatically by visual
inspection of sequences imported in sequence analysis
software Seqscape (Applied Biosystems) using the refer-
ence sequence NC 000017.9 from Genbank (http://www-
p53.iarc.fr/TP53sequence NC 000017-9.html). Sequencing
results were reevaluated by restriction fragment length
polymorphism (RFLP) with HaeIII, the cutting site of which
(GGCC) is abrogated by R249S mutation (GTCC) [22].
2.4. Analysis of HBX Status and Mutations. The method used
for HBX ampliﬁcation is based on the method described
by Ma and coworkers [5]. Four overlapping amplicons of
progressive length, starting at the 5  end of HBX sequence,
were generated, the shorter one covering the ﬁrst 139bp
and the longer one covering the whole gene sequence
(425bp). One common forward primer X1F was used inHepatitis Research and Treatment 3
all PCR (5 -GGGACGTCCTTTGTCTACGT-3 ), and four
diﬀerent reverse primers were used along HBX gene, X1R
(5 -GGGAGACCGCGTAAAGAGAG-3 ) (139bp), X2R (5 -
GTGCAGAGGTGAAGCGAAGT-3 )( 1 9 2 b p ) ,X 3 R( 5  -
CCCAACTCCTCCCAGTCTTT-3 )( 3 3 4 b p ) ,o rX 4 R( 5  -
GGCAGAGGTGAAAAAGTTGCA-3 ) (425bp). Fifty cycles
were performed for all reactions after activation of the
GoTaq Hot Star Polymerase at 94◦Cf o r2 m i n( 0 . 5 U ,
Promega) (denaturing at 94◦C for 45sec, annealing at 62◦C
for 45sec, and extension at 72◦Cf o r4 5 s e c )f o l l o w e db y
extension at 72◦C for 10min. Mutation analysis of HBX
gene was performed using nucleotide and protein alignment
with GenBank references HBX g e n e so fg e n o t y p eD( t h e
predominant genotype in Iran) with MEGA5 software [23].
2.5. HBS Ampliﬁcation and Genotype Determination in a
Patient from The Gambia. HBS gene was ampliﬁed from
free-circulating plasma DNA using a heminested PCR.
For the ﬁrst reaction, 2µLo fD N Aw e r eu s e dw i t h
primers S HBVpol1 (5 -CCTGCTGGTGGCTCCAGTTCA-
3 )a n dS HBVporv2 (5 -AAAGCCCAAAAGACCCAC-
AAT-3 ); PCR settings were 95◦C (15min); 40cycles of
95◦C (30sec), 60◦C (30sec), 72◦C (1min); then 72◦Cf o r
7 m i n .S e c o n ds t e pu s e d2 µL of the ﬁrst reaction and
primers S HBV123s (5 -TCGAGGATTGGGGACCCTG-3 )
and S HBVporv2 PCR settings were 95◦C (15min); 45cycles
of 95◦C (30s), 58◦C (30s), 72◦C (1min); then 72◦Cf o r
7min. 5µL of PCR products were puriﬁed using standard
ExoSap-IT (usb Corporation, Ohio, USA) enzyme, and
nucleotide sequences were determined for both strands
by automated dideoxy sequencing (sequencer AbiPrism
3100, Applied Biosystems, CA, USA). Direct sequencing
on ampliﬁed fragments was performed using the primers:
S HBV123s, S HBVporv2 and S HBV778r (5 -GAGGTA-
TAAAGGGACTCAAG-3 ). HBV genotypes and subtypes
were determined as previously described [24] and a phylo-
genetic tree was made using the software MEGA5 [23].
3. Results andDiscussion
Of the initial 34 cases of archived HCC cases from Iran,
exon 7 was successfully and reproducibly analyzed in 18
cases and HBX mutations were analyzed in 21 cases. Other
samples could not be fully analyzed due to insuﬃcient
quality and/or low amount of extracted DNA. Table 1 shows
the characteristics of the 21 analyzed cases and the major
ﬁndings. Mean age was 56.4(±19.3) years and all except one
(5%) were men. HBV immunological data was available in
the medical ﬁles of 15 (71.4%) cases, including 6 (28.6%)
positive cases and 9 (42.8%) negative cases. Data was
not available for the other 6. Cirrhosis was histologically
conﬁrmed in 7 subjects (33.3%), absent in 7 (33.3%), and
no data was available for the rest (7; 33.3%). HBX was not
present in one case (4.8%), complete in 7 (38.1%), and 3 -
truncated in 12 (57.1%). Our results on HBX status showed
a higher proportion of 3 -truncated HBX,c o n c o r d a n tw i t h
a previous study which has reported a COOH-deletion in
about80%ofHCCfromChina[5].Moreover,ofthe20cases
positive for HBX (complete or 3 -truncated) only 6 were
Table 1:Characteristicsandmolecularstatusof21HCCcasesfrom
Iran.
Characteristics No. (%)
Mean age (±SD) 56.4 (±19.3)
Sex
Women 1 (4.8)
Men 20 (95.2)
HBV status
Positive 6 (28.6)
Negative 9 (42.8)
N/A 6 (28.6)
Cirrhosis
Present 7 (33.3)
Absent 7 (33.3)
N/A 7 (33.3)
TP53 mutation (R249S)
Absent 21 (100.0)
Present 0 (0.0)
HBV Double mutation (1762T/1764A)
Absent 21 (100.0)
Present 0 (0.0)
HBX status
Complete 8 (38.1)
3 -Truncated 12 (57.1)
Absent 1 (4.8)
N/A: Not available.
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Figure 1: Number of mutations along of HBx amino acids.
Mutation analysis was performed using alignment with GenBank
HBV references by MEGA5 software [23]. Four main mutation
points were amino acids 30, 78, 101, and 116.
positive by serology. Noteworthy, among the 6 cases without
information about HBV serology, all but one were positive
for HBX. Together, these observations suggest a relatively
high prevalence of occult HBV infection.
Both TP53 R249S mutations and double mutations
1762T/1764A in HBV genome have been considered as
hallmarks of aﬂatoxin-induced HCC in a context of HBV
chronic infection. Kuang et al. reported the detection of
these mutations in both plasma and tumor samples of
HCC cases and most importantly, they were detected in
some individuals up to 8 years before HCC diagnosis [13].
In this paper, we selected a small group of histologically
conﬁrmed HCC cases from Iran, where HCC is the 11th4 Hepatitis Research and Treatment
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Figure 2: Neighbor-joining phylogenetic analysis using HBS gene of genotype D. The four subgenotypes D1 to D4 sequences were extracted
from GenBank. The HCC R249S positive case from the case-control study from The Gambia is shown by an orange arrow and corresponds
to subgenotype D1 (green circle). Made by the software MEGA5 [23].
most common cancer and chronic HBV infection aﬀects
3% of the population and is considered as a major health
problem and probably the most common cause of HCC in
thisregion.MutationanalysisofTP53andHBX didnotshow
case positive for R249S or 1762T/1764A mutation, suggesting
that these two hallmarks of HCC were absent or infrequent
in this particular etiological context.
T h ep r e d o m i n a n tH B Vg e n o t y p ei nI r a ni sg e n o t y p eD ,
which is diﬀerent from the most common genotypes found
in highest incidence areas (genotypes B and C in South-
East Asia, genotypes E and A in West Africa, genotypes
A, G, and F in Americas). The sample size of our study
was small, and most of our samples were selected among
needle biopsies with tiny pieces of tissues, which limited theHepatitis Research and Treatment 5
success rate for amplifying DNA and obtain high quality
DNAtoperformacompletemolecularanalysis.Forexample,
we failed to amplify HBS gene for genotype analysis of
our cases, thus making it not possible to formally identify
the genotype of these patients. We thus relied on previous
publications from diﬀerent parts of Iran, which detected
genotype D as the predominant one [16–18]. Nevertheless,
our paper is the ﬁrst one that analyzed the molecular
hallmarks of carcinogenesis in HCC cases in an area of
high predominance of genotype D. The absence of double
mutations1762T/1764A inHCCinIran(Figure 1)showsthat
diﬀerent HBV genotypes may undergo speciﬁc mutations in
the process of hepatocarcinogenesis. The fact that genotype
D does not appear to acquire nor accumulate the mutations
that characterize the genotypes associated with HCC in areas
of high incidence may explain at least in part the relatively
low incidence of HCC in Iran and in other countries of
high prevalence of genotype D despite relatively high chronic
carriage of HBV in these populations. Interestingly, HBX
mutation analysis identiﬁed mutations in amino acids that
have not been noted in HBV genotypes from high incidence
areas so far. These include mutations at amino acid numbers
30, 78, 101, and 116 (Figure 1). This ﬁnding may represent
another molecular diﬀerence of liver carcinogenesis between
high and low risk regions. Further studies are needed to
understand the role of HBV genotypes and mutations that
are less common in low incidence regions.
The absence of TP53 R249S mutations in HCC from Iran
also suggests that the mechanisms of carcinogenesis involved
are distinct from those that drive hepatocarcinogenesis in
areas of highest incidence. Recent reports analyzing the
presence of AFB1 i nf o o da n dn u t sf r o mI r a nh a v ef a i l e d
to show signiﬁcant levels of fungal contamination [19–21].
Therefore, the population exposure to aﬂatoxin might be
low, although aﬂatoxin contamination is detectable in many
regionsspanningtheareasofhighprevalenceofthegenotype
Do fH B V .
The present paper highlights that genotype D and R249S
mutations are not incompatible or mutually exclusive in
HCC pathogenesis. Indeed, we report here a single HCC
casefromapreviouslydescribedcase-controlstudyfromThe
Gambia (West Africa) with HBV infection by genotype D1
(subtypeayw2)(Figure 2)andwiththepresenceoftheR249S
TP53 mutation [22, 25, 26]. This HCC case R249S-genotype
D1 is the ﬁrst one described so far having these molecular
characteristics. The patient is a 45-year-old man without
HBV double mutation. Several epidemiological studies have
shown that the risk of HCC is increased in the presence of
both HBV infection and AFB1 exposure. R249S mutation
has been shown to be detectable in plasma DNA and tumor
tissueofHCCcasesinChinaandinTheGambiawhereAFB1
and HBV infection are prevalent with genotypes B, C, A,
and E, respectively. However, this R249S mutation has never
been reported in the presence of HBV genotype D even in
India where predominance of HBV genotype D could be
considered as the major risk factor for liver carcinogenesis
possibly reinforced by the presence of AFB1 exposure
[8, 11].
4. Conclusion
Our results on HCC cases from Iran, an area with HBV
genotype D infection, failed to detect the molecular hall-
marks of the etiologic role of HBV chronic infection and
AFB1 exposure in liver carcinogenesis. Our ﬁndings are the
starting point for further studies to evaluate and to discover
the molecular mechanisms of HBV genotypes diﬀerently
distributed in high-risk regions. In addition, we described
here the ﬁrst case of HCC in a patient from The Gambia with
the TP53 R249S mutation and infection with HBV genotype
D1, showing that, despite its relative rarity, the association
between genotype D and TP53 R249S mutation may occa-
sionally occur. Further studies are needed to understand
the molecular mechanisms of synergy between HBV chronic
infection and aﬂatoxin mutagenesis in order to explain
why this association may operate more systematically with
certain, but not all, HBV genotypes. Such diﬀerence might
be of major importance to evaluate the impact of risk factors
on the incidence of HCC in diﬀerent parts of the world.
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